Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ERAS

Erasca Inc

Apr 10 • 04:00PM ET

17.01

-0.35 -2.02 %

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX ALNY RNA NTLA CRSP BEAM EDIT PFE AMGN

| Held by: VTI XBI IWM VXF IWN IBB SCHA VTWO TCAF FESM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.44	Insider Own	40.06%	Shs Outstand	284.16M	Perf Week	-4.49%
Market Cap	5.29B	Forward P/E	-	EPS next Y	-0.52	Insider Trans	-0.18%	Shs Float	186.31M	Perf Month	9.74%
Enterprise Value	5.06B	PEG	-	EPS next Q	-0.10	Inst Own	45.90%	Short Float	16.04%	Perf Quarter	192.77%
Income	-124.55M	P/S	-	EPS this Y	1.38%	Inst Trans	1.84%	Short Ratio	5.32	Perf Half Y	600.00%
Sales	0.00M	P/B	14.86	EPS next Y	-20.34%	ROA	-27.37%	Short Interest	29.89M	Perf YTD	357.26%
Book/sh	1.14	P/C	19.15	EPS next 5Y	-14.22%	ROE	-33.27%	52W High	18.20 -6.54%	Perf Year	1497.18%
Cash/sh	0.89	P/FCF	-	EPS past 3/5Y	39.56% 12.46%	ROIC	-33.91%	52W Low	1.02 1559.51%	Perf 3Y	521.94%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.43% 7.42%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	41.14%	Oper. Margin	-	ATR (14)	1.03	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	10.04	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	62.42	Recom	1.45
Dividend Gr. 3/5Y	- -	Current Ratio	10.04	EPS Q/Q	10.09%	SMA20	9.75%	Beta	1.05	Target Price	18.27
Payout	-	Debt/Eq	0.14	Sales Q/Q	-	SMA50	21.35%	Rel Volume	0.49	Prev Close	17.36
Employees	103	LT Debt/Eq	0.13	Earnings	Mar 12 AMC	SMA200	201.63%	Avg Volume	5.62M	Price	17.01
IPO	Jul 16, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.54% -	Trades		Volume	2,741,748	Change	-2.02%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-27-26	Resumed	Mizuho	Outperform	$16
Jan-07-26	Initiated	Piper Sandler	Overweight	$5
Oct-16-25	Initiated	Stifel	Buy	$4
Sep-03-25	Downgrade	BofA Securities	Buy → Underperform
Aug-18-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$2
Mar-26-25	Initiated	Raymond James	Outperform	$5
Nov-18-24	Initiated	Jefferies	Buy	$6
Mar-11-24	Initiated	CapitalOne	Overweight	$8
Jan-05-24	Downgrade	BofA Securities	Buy → Neutral	$11 → $6
Oct-11-23	Initiated	H.C. Wainwright	Buy	$10
Mar-30-23	Initiated	Mizuho	Buy	$9
Feb-24-23	Initiated	Goldman	Buy	$10
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$15

Show Previous Ratings

Mar-12-26 04:01PM	Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results (GlobeNewswire) -5.48% -7.03%
Mar-10-26 08:00AM	Erasca Exercises Option to Secure Worldwide Rights for ERAS-0015 Pan-RAS Molecular Glue to Include China, Hong Kong, and Macau (GlobeNewswire)
Mar-09-26 11:17AM	uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts (24/7 Wall St.)
Mar-06-26 09:45AM	TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS (Zacks)
Mar-05-26 04:10PM	Tango Therapeutics, Up 39% This Year, Surges Again On Another Cancer Pact (Investor's Business Daily)
07:01AM	Loading…
07:01AM	Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat (GlobeNewswire)
Feb-28-26 03:15PM	Erasca, Inc. (ERAS): A Bull Case Theory (Insider Monkey)
Feb-27-26 08:08PM	Erasca Conference: ERAS Teases 2026 Catalysts for Pan-RAS ERAS-0015 and Pan-KRAS ERAS-4001 (MarketBeat) +6.37%
Feb-24-26 08:00AM	Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 (GlobeNewswire)
Feb-13-26 02:07PM	Erasca Touts Early ERAS-0015 Responses, Potency Edge in Guggenheim Fireside Chat (MarketBeat)
Feb-05-26 08:00AM	Erasca to Present at Upcoming Conferences in February (GlobeNewswire) +5.69%
Feb-02-26 12:45PM	Up 460% in the Past Year, Should You Take a Gamble on This Speculative Stock? (Barchart)
04:16AM	Mizuho Initiates Erasca (ERAS) With 'Outperform' Rating and $16 PT (Insider Monkey)
Jan-30-26 09:48AM	Guggenheim More Than Doubles Erasca (ERAS) PT Following Clinical Progress and Updated Pipeline Models (Insider Monkey)
Jan-26-26 07:52AM	Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday? (Benzinga)
04:01PM	Loading…
Jan-23-26 04:01PM	Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jan-21-26 08:54PM	Erasca Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire)
Jan-20-26 04:01PM	Erasca Announces Proposed Public Offering of $150 Million of Common Stock (GlobeNewswire)
Jan-19-26 09:12PM	Erasca (ERAS) Soars 42% on Bullish Rating, PT Upgrade (Insider Monkey)
Jan-16-26 11:33AM	Erasca (ERAS) Touches 3-Year High as 4 Analysts Go Bullish; Gets 267% PT Hike (Insider Monkey)
09:06AM	Erasca Stock Surges 42% in a Week: Here's What You Should Know (Zacks)
08:00AM	Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape (PR Newswire)
Jan-15-26 04:34PM	These charts show the stock market giving investors a lot to like - for now - as the S&P 500 nears 7,000 (MarketWatch) +15.04%
04:12PM	David Vs. Goliath: Why Small Caps Are Crushing The Magnificent 7 (Benzinga)
05:09AM	Erasca (ERAS) Hits Fresh High Anew as Firm Gets up to 267% PT Hike (Insider Monkey)
Jan-14-26 10:52AM	Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff (PR Newswire) +10.73%
07:08AM	Erasca (ERAS) Climbs to 3-Year High as Analyst Hikes PT by 83% (Insider Monkey)
Jan-12-26 08:00AM	Erasca Announces Promising Early Clinical Data for ERAS-0015 and 2026-2027 Milestones (GlobeNewswire) -7.84%
Jan-08-26 01:21PM	What's Going With Cancer Biotech Erasca Stock On Thursday? (Benzinga) +12.38%
Jan-07-26 03:33PM	Revolution Medicines stock surges over 20% on potential AbbVie acquisition (Investing.com) +42.42%
08:00AM	Loading…
Jan-06-26 08:00AM	Erasca to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-25 10:17AM	Platform Technologies Drive $211B Surge in Precision Cancer Treatment (PR Newswire)
Nov-29-25 01:26AM	Analyst Confidence High in Erasca (ERAS) Amid Pipeline Advancement and Earlier Q3 2025 Results (Insider Monkey)
Nov-25-25 09:08AM	Erasca to Present at the 8th Annual Evercore Healthcare Conference (GlobeNewswire) +6.23%
Nov-12-25 04:01PM	Erasca Reports Third Quarter 2025 Business Updates and Financial Results (GlobeNewswire) +12.29%
Nov-06-25 08:00AM	Erasca Announces Issuance of a U.S. Patent Covering Pan-RAS Molecular Glue ERAS-0015 (GlobeNewswire)
Nov-04-25 08:00AM	Erasca to Present at Upcoming Conferences in November (GlobeNewswire)
Oct-27-25 01:09PM	Can Centene's Q3 Earnings Escape Industry's Cost Headwinds? (Zacks)
Oct-23-25 12:42PM	Will Lower Patient Days Affect Tenet Healthcare's Q3 Earnings? (Zacks)
Oct-21-25 12:13PM	Will Rising Costs Hurt HCA Healthcare Q3 Earnings? Key Estimates Here (Zacks)
Sep-02-25 08:00AM	Erasca to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference (GlobeNewswire)
Aug-12-25 04:01PM	Erasca Reports Second Quarter 2025 Business Updates and Financial Results (GlobeNewswire) +5.41%
Jul-31-25 11:40PM	Erasca Receives FDA Clearance for First-in-Class Pan-KRAS Inhibitor, ERAS-4001, for Solid Tumors (Insider Monkey) -8.71%
Jun-30-25 11:02AM	Oncology Innovation Just Hit a Turning Point -- Here's What to Watch (PR Newswire)
Jun-02-25 08:00AM	Erasca Announces IND Clearance for Potential First-in-Class and Best-in-Class Pan-KRAS Inhibitor ERAS-4001 (GlobeNewswire)
May-29-25 08:00AM	Erasca to Present at Upcoming Investor Conferences in June (GlobeNewswire) +31.82%
May-13-25 04:05PM	Erasca Reports First Quarter 2025 Business Updates and Financial Results (GlobeNewswire)
08:00AM	Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway (GlobeNewswire)
May-07-25 08:00AM	Erasca to Present at the Bank of America Securities Health Care Conference (GlobeNewswire)
Apr-29-25 04:05PM	Erasca Presents New Preclinical Data Reinforcing Best-in-Class Potential of RAS-Targeting Franchise at the 2025 AACR Annual Meeting (GlobeNewswire)
Apr-25-25 11:33AM	Erasca, Inc.: Carving A Different Niche In RAS Signaling (Seeking Alpha)
Apr-16-25 10:16AM	Is Erasca Inc. (NASDAQ:ERAS) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Mar-25-25 04:31PM	Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting (GlobeNewswire)
Mar-20-25 04:01PM	Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results (GlobeNewswire)
Jan-31-25 08:00AM	Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference (GlobeNewswire)
Jan-21-25 09:35AM	Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) (Zacks)
Jan-20-25 09:35AM	Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround (Zacks)
Jan-17-25 09:35AM	Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) (Zacks)
Jan-16-25 09:35AM	Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS) (Zacks)
Jan-07-25 08:00AM	Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-24 11:26AM	Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment (PR Newswire)
Nov-15-24 09:55AM	Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-12-24 04:01PM	Erasca Reports Third Quarter 2024 Business Updates and Financial Results (GlobeNewswire)
Nov-05-24 08:00AM	Erasca to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-24-24 08:00AM	Erasca Announces Strong Momentum for Naporafenib and RAS Targeting Franchise (GlobeNewswire)
Sep-25-24 08:00AM	Erasca to Present Preliminary SEACRAFT-1 Phase 1 Data for Naporafenib Plus Trametinib in RAS Q61X Mutant Solid Tumors as Oral Presentation at 36th EORTC-NCI-AACR Symposium (GlobeNewswire) +8.09%
Aug-29-24 08:00AM	Erasca to Present at Upcoming Investor Conferences in September (GlobeNewswire)
Aug-12-24 10:53PM	ERAS Stock Earnings: Erasca Misses EPS for Q2 2024 (InvestorPlace) +7.92%
04:01PM	Erasca Reports Second Quarter 2024 Business Updates and Financial Results (GlobeNewswire)
Jun-18-24 12:14PM	Erasca kicks off Phase III trial for naporafenib combo therapy in melanoma (Clinical Trials Arena)
08:00AM	Erasca Initiates SEACRAFT-2 Pivotal Phase 3 Trial Evaluating Naporafenib Plus Trametinib in Patients with NRAS-Mutant Melanoma (GlobeNewswire)
Jun-04-24 09:55AM	Should You Buy Erasca, Inc. (ERAS) After Golden Cross? (Zacks)
May-29-24 08:00AM	Erasca to Present at Upcoming Investor Conferences in June (GlobeNewswire)
May-21-24 04:05PM	Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
May-17-24 07:14AM	Erasca Acquires 2 Exclusive Worldwide Licenses for Preclinical RAS Programs (MT Newswires) +6.49%
05:51AM	Erasca restructures; Novartis moves to complete MorphoSys deal (BioPharma Dive)
05:31AM	Erasca lays off 18% while swapping out KRAS program for fresh anti-tumor options (FierceBiotech.com)
04:11AM	Erasca Prices $160 Million Common Stock Offering (MT Newswires)
May-16-24 08:02PM	Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise (GlobeNewswire)
08:00PM	Erasca Announces Pricing of Underwritten Offering of Common Stock (GlobeNewswire)
May-08-24 11:55PM	ERAS Stock Earnings: Erasca Misses EPS for Q1 2024 (InvestorPlace) -8.84%
04:01PM	Erasca Reports First Quarter 2024 Business Updates and Financial Results (GlobeNewswire)
May-07-24 08:00AM	Erasca to Present at the Bank of America Health Care Conference (GlobeNewswire)
Apr-24-24 04:05PM	Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting (GlobeNewswire)
Apr-23-24 12:00PM	Erasca (ERAS) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
Apr-01-24 04:56PM	Erasca, Inc. (NASDAQ:ERAS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-29-24 05:31AM	Erasca Inc (ERAS) Aligns with EPS Projections, Reveals Robust Balance Sheet and Key Clinical ... (GuruFocus.com)
Mar-27-24 10:53PM	ERAS Stock Earnings: Erasca Beats EPS for Q4 2023 (InvestorPlace)
08:30PM	Erasca Announces $45 Million Oversubscribed Private Placement Financing (GlobeNewswire)
04:01PM	Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results (GlobeNewswire)
Feb-14-24 08:00AM	Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials (GlobeNewswire)
Feb-01-24 08:00AM	Erasca to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-03-24 08:00AM	Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-20-23 01:34PM	3 Penny Stocks Youll Regret Not Buying Soon: December Edition (InvestorPlace) -5.08%
Dec-11-23 08:00AM	Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma (GlobeNewswire)
Nov-28-23 08:00AM	Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway (GlobeNewswire) -11.38%
Nov-09-23 04:01PM	Erasca Reports Third Quarter 2023 Financial Results and Business Updates (GlobeNewswire) -8.64%
Nov-08-23 08:00AM	Erasca to Present at Upcoming Investor Conferences in November (GlobeNewswire)
Oct-12-23 11:28AM	Insiders Are Betting Millions on These 2 Stocks Heres Why You Might Want to Follow Their Lead (TipRanks)
Oct-10-23 03:56PM	Why Shares of Erasca Are Jumping Tuesday (Motley Fool) +13.18%

Erasca, Inc. is a clinical stage precision oncology company. It focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. It has assembled a wholly owned or controlled RAS/MAPK pathway focused pipeline comprising modality-agnostic programs. The company was founded by Jonathan E. Lim and Kevan Shokat on July 2, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Garner Ebun	Chief Legal Officer	Apr 01 '26	Option Exercise	1.70	80,000	136,000	105,076	Apr 03 09:00 AM
Garner Ebun	Chief Legal Officer	Apr 01 '26	Sale	16.40	80,000	1,312,000	25,076	Apr 03 09:00 AM
Ebun Garner	Officer	Apr 01 '26	Proposed Sale	16.40	80,000	1,312,355		Apr 01 02:19 PM
Erasca Foundation	Foundation	Mar 16 '26	Proposed Sale	14.02	8,333	116,855		Mar 16 02:38 PM
Morris Shannon	Chief Medical Officer	Mar 04 '26	Option Exercise	1.70	20,000	34,000	20,000	Mar 06 09:00 AM
Morris Shannon	Chief Medical Officer	Mar 04 '26	Sale	15.04	20,000	300,760	0	Mar 06 09:00 AM
Shannon Morris	Officer	Mar 04 '26	Proposed Sale	15.04	20,000	300,769		Mar 04 05:38 PM
Erasca Foundation	Foundation	Feb 17 '26	Proposed Sale	11.91	8,333	99,245		Feb 17 02:27 PM
Erasca Foundation	Foundation	Jan 15 '26	Proposed Sale	8.23	8,333	68,574		Jan 15 10:43 AM
Garner Ebun	General Counsel & Corp. Sec.	Jan 07 '26	Option Exercise	1.70	120,000	204,000	145,076	Jan 08 09:20 PM
Garner Ebun	General Counsel & Corp. Sec.	Jan 07 '26	Sale	5.59	120,000	670,812	25,076	Jan 08 09:20 PM
Ebun Garner	Officer	Jan 07 '26	Proposed Sale	5.59	120,000	670,809		Jan 07 03:58 PM
Erasca Foundation	Foundation	Dec 15 '25	Proposed Sale	3.65	8,333	30,439		Dec 15 08:11 PM
Erasca Foundation	Erasca Foundation	Nov 17 '25	Proposed Sale	2.60	8,333	21,626		Nov 17 04:27 PM
Erasca Foundation	Erasca Foundation	Oct 15 '25	Proposed Sale	2.47	8,333	20,591		Oct 15 03:43 PM
Erasca Foundation	Erasca Foundation	Sep 15 '25	Proposed Sale	1.55	8,333	12,942		Sep 15 04:21 PM
Erasca Foundation	Erasca Foundation	Aug 15 '25	Proposed Sale	1.54	8,333	12,835		Aug 15 03:21 PM
Erasca Foundation	Affiliate	Jul 15 '25	Proposed Sale	1.42	8,333	11,817		Jul 15 03:56 PM
Erasca Foundation	Affiliate	Jun 16 '25	Proposed Sale	1.42	8,333	11,813		Jun 16 03:16 PM
Erasca Foundation	Affiliate	May 15 '25	Proposed Sale	1.19	8,333	9,902		May 15 04:15 PM
Erasca Foundation	Affiliate	Apr 15 '25	Proposed Sale	1.22	8,333	10,165		Apr 15 03:56 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ERAS

Erasca Inc

Upgrade your Finviz experience